Early aggressive therapy for severe extensive ulcerative colitis

World Journal of Gastroenterology

Volumn 15, Issue 33, 2009, Pages 4218-4219

  Cui, De Jun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Infliximab; Top down therapy; Ulcerative colitis

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHRONIC DRUG ADMINISTRATION; COLON SURGERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAINTENANCE THERAPY; QUALITY OF LIFE; RISK REDUCTION; TOXIC MEGACOLON; ULCERATIVE COLITIS; NOTE;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 70449715315     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4218     Document Type: Article

References (8)

1. Cury DB, Cury Mde S, Elias GV, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009; 15: 1771-1773
2. Travis SPL, Stange EF, Lémann M, ∅resland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008; 2: 24-62
3. Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH, Walters J, Carpani M, Westaby D, Thillainayagam A, Bansi D, Ghosh S. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 2009; 29: 308-314
4. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 (Pubitemid 41770166)
5. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 3: CD005112
6. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442; quiz 464
7. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508
8. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 1230-1239